Fred R. Hirsch, MD, PhD, shares a message with oncologists regarding molecular testing in patients with lung cancer. He says the most important message is that molecular characterization of the patient’s tumor must be done in order to best treat the patient.
Fred R. Hirsch, MD, PhD, professor of medicine and executive director for the Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, shares a message with oncologists regarding molecular testing in patients with lung cancer. He says the most important message is that molecular characterization of the patient’s tumor must be done in order to best treat the patient.
It sounds simple, but Hirsch says not all patients with lung cancer undergo molecular testing at this time, especially in the community setting. It is not natural in that setting to get molecular testing on every patient’s tumor, but it is necessary.
Today’s lung cancer treatments are mainly based on the molecular profile of patients, especially in the setting of advanced disease. Understanding a patient’s molecular profile is essential in selecting the right treatment.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More